However, various studies have clarified that the overexpression of IGFBP2 are related to poorer prognosis in breast cancer [26], endometrial cancer [27], colorectal cancer [28], pancreatic ductal adenocarcinoma [23], lung cancer [29], and glioblastoma [21]. Here, IGFBP2 is linked to pancreatic ductal adenocarcinoma.